Skip to content
Bored Studies
RecruitingAccepts healthy volunteersEarly Phase 1

Glutamatergic Adaptation to Stress as a Mechanism for Anhedonia and Treatment Response With Ketamine

Emory University · with National Institute of Mental Health (NIMH) · NCT05327699

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18–65 · All sexes
Healthy volunteers
Accepted
Study type
Interventional · Early Phase 1
Target enrollment
140
US sites recruiting
1
Study start
November 8, 2022
Record last updated
May 26, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The main purpose of this study is to investigate the effects of ketamine on decision-making and emotion processing in a sample of individuals diagnosed with Major Depressive Disorder (MDD).

Being studied: Ketamine; Placebo

Conditions: Major Depressive Disorder

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

MDD Patients

  • willing and able to give written informed consent
  • men or women, 18-65 years of age
  • primary diagnosis of DSM-V MDD, current, as diagnosed by the SCID-I
  • score of ≥20 on the Beck Depression Inventory, which will include patients characterized as having "moderate/severe" (20-28) or "very-severe" (29-63) depressive symptoms
  • off all antidepressant therapy for at least 8 weeks prior to the baseline visit

Healthy Controls

  • willing and able to give written informed consent
  • men or women, 18-65 years of age

Exclusion Criteria

MDD Patients

  • history of any bipolar disorder or psychotic disorder
  • active psychotic symptoms of any type
  • substance abuse/dependence within 6 months of study entry (as determined by SCID)
  • unstable cardiovascular, endocrinologic, hematologic, hepatic, renal, or neurologic disease (as determined by physical examination and laboratory testing), including upper respiratory disease or asthma, glaucoma or porphyria.
  • active suicidal ideation as determined by a score ≥3 on the Columbia Suicide Severity Rating Scale (C-SSR)
  • use of any recreational drugs as confirmed by urine drug screen at the time of scanning
  • pregnancy or lactation
  • use of glucocorticoids at any time during the study
  • Raynaud's disease that may interfere with the cold-pressor
  • contraindications for MRI
  • MMSE score \<28
  • elevated blood pressure prior to infusion (systolic > 160 or diastolic >100)
  • history of treatment resistance as determined by ATRQ
  • prior adverse reaction to ketamine
  • use of antipsychotic medications
  • use of greater than 2mg daily of lorazepam or similar benzodiazipine.
  • Regular smoker as self-reported

Healthy Controls

  • evidence of any psychiatric disorder with exception of specific phobia, and no history of any psychiatric disorder except mild past substance use disorder as diagnosed by the SCID-I
  • history of any substance abuse within the last 6 months
  • use of any recreational drugs as confirmed by urine drug screen at the time of scanning
  • pregnancy or lactation
  • use of glucocorticoids at any time during the study
  • Raynaud's disease that may interfere with the cold-pressor
  • contraindications for MRI
  • MMSE score \<28
  • Regular smoker as self-reported

Recruiting US locations

  • Emory University

    Atlanta, GA 30322

    Site contact: Michael Treadway, PhD · (404) 727-7541 · ketaminestudy@emory.edu

Study contacts (from the official record)

  • Michael Treadway, PhD · (404) 727-7541 · ketaminestudy@emory.edu
Glutamatergic Adaptation to Stress as a Mechanism for Anhedonia… (NCT05327699) | Bored Studies